Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery

Ann Oncol. 2008 Sep;19(9):1659-61. doi: 10.1093/annonc/mdn540. Epub 2008 Aug 5.
No abstract available

Publication types

  • Letter

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Animals
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Bevacizumab
  • Cohort Studies
  • Colectomy / methods
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / pathology*
  • Colorectal Neoplasms / surgery
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / secondary*
  • Liver Neoplasms / surgery
  • Male
  • Neoadjuvant Therapy
  • Neoplasm Recurrence, Local / prevention & control*
  • Neoplasm, Residual / drug therapy
  • Prospective Studies
  • Risk Assessment
  • Treatment Outcome
  • Tumor Burden / drug effects

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab